- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- Lucentis (Ranibizumab)
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 311
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- ADVM-022
- Genetic
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection
- Drug
- Lead sponsor
- Rophibio, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 434 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Erie, Pennsylvania + 3 more
- Conditions
- Neovascular (Wet) Age-related Macular Degeneration
- Interventions
- SKG0106
- Genetic
- Lead sponsor
- Skyline Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Katy, Texas • Norfolk, Virginia
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- OTX-TKI/Sham, Aflibercept/Sham
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Bakersfield, California • Oxnard, California • Altamonte Springs, Florida + 3 more
- Conditions
- Retinal Hemorrhage, Macular Degeneration
- Interventions
- vitrectomy with subretinal lucentis
- Drug
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Exudative Age Related Macular Degeneration
- Interventions
- Ranibizumab Injection [Lucentis]
- Drug
- Lead sponsor
- Southeast Clinical Research Associates, LLC
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Statesville, North Carolina
- Conditions
- Age-related Macular Degeneration
- Interventions
- RBM-007 Injectable Solution
- Drug
- Lead sponsor
- Ribomic USA Inc
- Industry
- Eligibility
- 55 Years to 99 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Sacramento, California • Stanford, California • Walnut Creek, California
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- All participants
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 18,457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- AngioVue SD-OCT
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Age-related Macular Degeneration
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,097 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 99
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 91 more
- Conditions
- Macular Degeneration
- Interventions
- bevasiranib, ranibizumab
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fresno, California + 47 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- OTX-TKI, Aflibercept
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 825 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 84
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 73 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
- Interventions
- Ixo-vec, Aflibercept
- Genetic · Drug
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 75
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Intravitreal Aflibercept Injection 2mg
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 115
- States / cities
- Birmingham (2 Locations), Alabama • Phoenix (2 Locations), Arizona • Tucson (2 Locations), Arizona + 112 more
- Conditions
- Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- aflibercept 8 mg PFS
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 2
- States / cities
- Bellaire, Texas • The Woodlands, Texas
- Conditions
- Age-Related Macular Degeneration
- Interventions
- 0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122, 4.0 mg of DE-122
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 5
- States / cities
- Mountain View, California • Walnut Creek, California • Jackson, Michigan + 2 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- OTX-TKI (axitinib implant), Aflibercept
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 97
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 81 more
- Conditions
- Healthy Volunteers
- Interventions
- Weekly subcutaneous administration of Migaldendranib (MGB)
- Drug
- Lead sponsor
- Ashvattha Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Age-Related Macular Degeneration
- Interventions
- NG101 AAV gene therapy
- Genetic
- Lead sponsor
- Elisigen, Inc.
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
- Interventions
- UBX1325
- Drug
- Lead sponsor
- Unity Biotechnology, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Huntington Beach, California • Miami, Florida + 5 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Brolucizumab 6 mg, Aflibercept 2 mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 63
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Arcadia, California + 56 more
- Conditions
- Age-Related Maculopathy
- Interventions
- Rheopheresis
- Device
- Lead sponsor
- OccuLogix
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 18 more